Methods and compositions for the treatment or prevention of amyloidosis are provided. In some embodiments, the methods comprise administering to the subject a therapeutically effective amount of at least one catabolic enzyme or a biologically active fragment thereof. Such methods and compositions may be employed to reduce, prevent, degrade and/or eliminate amyloid formation in the lysosome and/or extracellularly.

Methods and compositions for the treatment or prevention of amyloidosis are provided. In some embodiments, the methods comprise administering to the subject a therapeutically effective amount of at least one catabolic enzyme or a biologically active fragment thereof. Such methods and compositions may be employed to reduce, prevent, degrade and/or eliminate amyloid formation in the lysosome and/or extracellularly.

One or more quorum silencing enzymes entrapped in an organopolysiloxane matrix, formulations comprising the enzymes, methods for obtaining the entrapped enzymes by co-gelation and methods of treating intestinal diseases.

A therapeutic agent for the treatment of toxemia, preeclampsia and eclampsia and a method for preparing the therapeutic agent are disclosed. The therapeutic agent is a stable pharmaceutical preparation containing, but not limited to, digestive/pancreatic enzymes. The therapeutic agent may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic agent may be made orally, through injection, by adherence of a medicated patch or by other methods. Further, a method of using the presence of chymotrypsin in the maternal GI tract as a biomarker, to determine the likelihood of developing preeclampsia, a pregnancy induced hypertension, and eclampsia/toxemia is disclosed.

A therapeutic agent for the treatment of toxemia, preeclampsia and eclampsia and a method for preparing the therapeutic agent are disclosed. The therapeutic agent is a stable pharmaceutical preparation containing, but not limited to, digestive/pancreatic enzymes. The therapeutic agent may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic agent may be made orally, through injection, by adherence of a medicated patch or by other methods. Further, a method of using the presence of chymotrypsin in the maternal GI tract as a biomarker, to determine the likelihood of developing preeclampsia, a pregnancy induced hypertension, and eclampsia/toxemia is disclosed.

The invention relates to a formulation of at least one digestive enzyme, the formulation comprising solid lipid particles, the solid lipid particles being: between 50 μm and 1200 μm in size, strictly hydrophobic, free of water, of organic solvent, of surfactant compound and of polymer, and comprising: at least one digestive enzyme, a strictly hydrophobic, non-hygroscopic waxy matrix, in which said at least one digestive enzyme: has homogeneous distribution in each solid lipid particle of the formulation, is distributed without a distribution gradient towards the interior of the waxy matrix, and represents between 0.1% and 90% of the mass of the formulation, the formulation having a melting point of between 20° C. and 65° C.

The invention relates to a formulation of at least one digestive enzyme, the formulation comprising solid lipid particles, the solid lipid particles being: between 50 μm and 1200 μm in size, strictly hydrophobic, free of water, of organic solvent, of surfactant compound and of polymer, and comprising: at least one digestive enzyme, a strictly hydrophobic, non-hygroscopic waxy matrix, in which said at least one digestive enzyme: has homogeneous distribution in each solid lipid particle of the formulation, is distributed without a distribution gradient towards the interior of the waxy matrix, and represents between 0.1% and 90% of the mass of the formulation, the formulation having a melting point of between 20° C. and 65° C.

The present document describes a non-carcinogenic cream for delivery of active ingredients in the dermis of a patient, which comprises a synergistic combination of about 10 to 25% of oil about 10 to 25% of emulsifier about 1 to 12% of preservative about 45 to 80% of water, aloe water or hamamelis water; and about 1 to 25% of at least one homeopathic active ingredient chosen from pancreatinum, ruta graveolens, ledum palustre, colchicum autumnale, symphytum officinalis, salix alba, harpagophytum, bryonia, capsicum, rhododendron, benzoic acid, salicilicum acid, arnica montana, atropa belladonna, achillea millefolium, hamamelis, agaricus, aesculus, mercurius solubilis, mercurius iodatus, conium maculatum, echinacea angustifolia, echinacea purpurea, scrofularia nosada, pulsatilla, aconitum napellus, hypericum perforatum, bellis perennis, matricaria chamomilla, ranunculus, phytolacca decandra, dulcamara solanum, kalmia, actea racemosa, spigelia, gnaphalium, calendula officinalis, hepar sulphuris, somniferrum, calcarea fluorica, thiosinaminum, hydrastis, arctium lappa, gallium aparine, urtica urens, aloe, graphite, petroleum or a synergistic combination thereof.

The present document describes a non-carcinogenic cream for delivery of active ingredients in the dermis of a patient, which comprises a synergistic combination of about 10 to 25% of oil about 10 to 25% of emulsifier about 1 to 12% of preservative about 45 to 80% of water, aloe water or hamamelis water; and about 1 to 25% of at least one homeopathic active ingredient chosen from pancreatinum, ruta graveolens, ledum palustre, colchicum autumnale, symphytum officinalis, salix alba, harpagophytum, bryonia, capsicum, rhododendron, benzoic acid, salicilicum acid, arnica montana, atropa belladonna, achillea millefolium, hamamelis, agaricus, aesculus, mercurius solubilis, mercurius iodatus, conium maculatum, echinacea angustifolia, echinacea purpurea, scrofularia nosada, pulsatilla, aconitum napellus, hypericum perforatum, bellis perennis, matricaria chamomilla, ranunculus, phytolacca decandra, dulcamara solanum, kalmia, actea racemosa, spigelia, gnaphalium, calendula officinalis, hepar sulphuris, somniferrum, calcarea fluorica, thiosinaminum, hydrastis, arctium lappa, gallium aparine, urtica urens, aloe, graphite, petroleum or a synergistic combination thereof.

Disclosed herein are methods of using coated digestive enzyme preparations and enzyme delivery systems and pharmaceutical compositions comprising the preparations for treatment of subjects having behavioral disorders, neurological disorders or mental health disorders. Disclosed herein are methods of treating core and non-core symptoms of behavioral disorders, neurological disorders or mental health disorders. Also disclosed herein are products for use in methods of treatment and methods of making the same.